PubRank

Hans Erik Johnsen

Author PubWeight™ 27.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003 2.65
2 Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006 2.26
3 FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance. Br J Haematol 2002 2.07
4 European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014 1.57
5 Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006 1.10
6 The in vivo toxicity of hydroxyurea depends on its direct target catalase. J Biol Chem 2010 0.99
7 In multiple myeloma clonotypic CD38- /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 2004 0.97
8 Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005 0.97
9 Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 2011 0.96
10 In-stent neo-intimal hyperplasia after stem cell mobilization by granulocyte-colony stimulating factor Preliminary intracoronary ultrasound results from a double-blind randomized placebo-controlled study of patients treated with percutaneous coronary intervention for ST-elevation myocardial infarction (STEMMI Trial). Int J Cardiol 2005 0.95
11 Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1. J Virol 2009 0.92
12 Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003 0.90
13 Multiplex reverse transcription polymerase chain reaction screening in acute myeloid leukemia detects cytogenetically unrevealed abnormalities of prognostic significance. Haematologica 2005 0.88
14 MyelomA Genetics International Consortium. Leuk Lymphoma 2012 0.86
15 Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leuk Lymphoma 2011 0.84
16 Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol 2005 0.82
17 Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol 2002 0.82
18 Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition. BMC Bioinformatics 2014 0.81
19 Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor. Brief Bioinform 2014 0.80
20 C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance. Leuk Lymphoma 2003 0.80
21 Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank. Cytometry B Clin Cytom 2014 0.78
22 Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma 2014 0.77
23 Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. Cytometry B Clin Cytom 2012 0.77
24 The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. Leuk Lymphoma 2002 0.76
25 Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes. Leuk Res 2013 0.76
26 FGFR3 dysregulation and clinical outcome in myeloma. Br J Haematol 2003 0.75
27 A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells. BMC Genomics 2012 0.75
28 Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review. Dan Med J 2016 0.75
29 [Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?]. Ugeskr Laeger 2006 0.75
30 [Complete remission after Rituximab treatment in refractory hairy cell leukemia]. Ugeskr Laeger 2008 0.75
31 [Mesenchymal stem cell therapy--the key to regenerative medicine?]. Ugeskr Laeger 2003 0.75
32 Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol 2005 0.75